Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar 27:2018:9745804.
doi: 10.1155/2018/9745804. eCollection 2018.

Efficacy of Suxiao Jiuxin Pill on Coronary Heart Disease: A Meta-Analysis of Randomized Controlled Trials

Li Ren  1 , Jie Wang  1 , Ling Feng  1 , Shuli Wang  1 , Jun Li  1
Affiliations
Review

Efficacy of Suxiao Jiuxin Pill on Coronary Heart Disease: A Meta-Analysis of Randomized Controlled Trials

Li Ren et al. Evid Based Complement Alternat Med. .

Abstract

Suxiao jiuxin pill is considered an effective ancillary drug in patients with coronary heart disease. Although numerous small, single-center clinical trials have been conducted, the benefits and harms of suxiao jiuxin pill remain controversial. We performed a meta-analysis to clarify the efficacy of suxiao jiuxin pill on patients with coronary heart disease. Randomized controlled trials were identified by using the Cochrane Library, PubMed, Web of Science, Embase, Wanfang, Weipu, and China Knowledge Resource Integrated databases (until June 2016). Pooled relative risks (RR), weighted mean differences (WMD), and 95% confidence intervals (95% CIs) were estimated using random-effects models. Forty-one trials involving 6276 patients were included in our analysis. Administration of suxiao jiuxin pill significantly improved electrocardiogram (ECG) results when compared with other therapies (RR 1.32, 95% CI 1.26 to 1.38, and P < 0.001). Subgroup analyses revealed that suxiao jiuxin pills improve ECG results more than salvia tablets (RR 1.54, 95% CI 1.41 to 1.67, and P < 0.001), isosorbide dinitrate (RR 1.14, 95% CI 1.21 to 1.44, and P = 0.001), nitroglycerin (RR 1.35, 95% CI 1.16 to 1.56, and P < 0.001), and other drugs (RR 1.32, 95% CI 1.21 to 1.44, and P < 0.001). Available evidence additionally suggests that suxiao jiuxin pills could significantly reduce total cholesterol (WMD -0.62 mmol/L, 95% CI -1.06 to -0.18 mmol/L, and P = 0.005) and low-density lipoprotein (LDL) levels (WMD -1.12 mmol/L, 95% CI -1.42 to -0.82 mmol/L, and P < 0.001) and increase high-density lipoprotein (HDL) levels (WMD 0.32 mmol/L, 95% CI 0.07 to 0.58 mmol/L, and P = 0.014). However, no significant differences were observed in total triglyceride levels, plasma viscosity, hematocrit, and fibrinogen. No incidences of adverse reactions were observed after administration of suxiao jiuxin pill. Improvements in ECG results and lipid profiles were also observed after suxiao jiuxin administration compared to other therapies. It also decreased low-cut and high-cut whole blood viscosity without significant adverse reactions.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Process used to select relevant studies for inclusion in the meta-analysis.
Figure 2
Figure 2
Relative risks for ECG improvement in the treatment and control groups.
Figure 3
Figure 3
Relative risks for ECG improvement in the various subgroups.
Figure 4
Figure 4
Funnel plot of studies included in the meta-analysis.
See this image and copyright information in PMC

References

    1. Yoon S. S., Dillon C. F., Illoh K., Carroll M. Trends in the Prevalence of Coronary Heart Disease in the U.S.: National Health and Nutrition Examination Survey, 2001–2012. American Journal of Preventive Medicine. 2016;51(4):437–445. doi: 10.1016/j.amepre.2016.02.023. - DOI - PMC - PubMed
    1. Zeidan R. K., Farah R., Chahine M. N., et al. Prevalence and correlates of coronary heart disease: First population-based study in Lebanon. Vascular Health and Risk Management. 2016;12:75–84. doi: 10.2147/VHRM.S97252. - DOI - PMC - PubMed
    1. Haim M., Hoshen M., Reges O., Rabi Y., Balicer R., Leibowitz M. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. Journal of the American Heart Association. 2015;4(1, article e001486) doi: 10.1161/JAHA.114.001486. - DOI - PMC - PubMed
    1. Kannel W. B., Abbott R. D., Savage D. D., McNamara P. M. Coronary heart disease and atrial fibrillation: The Framingham Study. American Heart Journal. 1983;106(2):389–396. doi: 10.1016/0002-8703(83)90208-9. - DOI - PubMed
    1. Lokshyn S., Mewis C., Kuhlkamp V. Atrial fibrillation in coronary artery disease. International Journal of Cardiology. 2000;72(2):133–136. doi: 10.1016/S0167-5273(99)00180-1. - DOI - PubMed